Amgen: Humira Interchangeability ‘A Nice To Have, Not A Need To Have’
‘Many’ Biosimilars Sponsors ‘Struggled’ With Key Issue Of Continuous Supply
Amgen management spoke at length about biosimilars during the company’s two-and-a-half-hour-long business review meeting, with the launch of its Amjevita (adalimumab-atto) biosimilar now less than a year away.
